This approach has been previously taken with other potential resistance modulators from different mechanisms; for example, in studies combining the DNA methyltransferase inhibitor decitabine [40], the flavone glycoside scutellarin [41], or Kruppel-like factor 5 inhibitor, ML264 [42], with Oxa in CRC cell lines or patient-derived organoids. This evidence concerns the gene KLF5 and colorectal carcinoma.